Search alternatives:
less decrease » levels decreased (Expand Search), largest decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
less decrease » levels decreased (Expand Search), largest decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
801
-
802
-
803
-
804
-
805
Flow chart of experimental protocol.
Published 2024“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
-
806
A representative ultrasound axis image.
Published 2024“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
-
807
-
808
-
809
-
810
-
811
-
812
-
813
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
814
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
815
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
816
-
817
Demethylation Pathway of Methylmercury in the Spleen and Peripheral Organs of Bluefin TunaImplications for Fish Consumers
Published 2025“…While the spleen is well-known as the body’s largest immune organ, its role in detoxification is less recognized. Here, we used high-energy-resolution X-ray absorption spectroscopy to examine the chemical forms of mercury (Hg) in ABFT tissues, building on prior analysis of stable Hg isotopes. …”
-
818
-
819
-
820